Pharmacy July 8, 2021 2 min read Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study Veena Hoffman; Jesper Hallas; Marie Linder; Andrea V Margulis; Brandon T Suehs; Alejandro Arana; Kelesitse Phiri; Cheryl Enger; Libby Horter; Ingvild Odsbu; Morten Olesen; Susana Perez-Gutthann; Yihua Xu; Nina Sahlertz Kristiansen; Kwame Appenteng; Stefan de Vogel; John D Seeger; mirabegron PMR-PASS study group Read More
Pharmacy April 9, 2021 1 min read A Real-World Comparison of Cardiovascular, Medical and Costs Outcomes in New Users of SGLT2 Inhibitors versus GLP-1 Agonists Insiya B Poonawalla; Andy T Bowe; Michael C Tindal; Yunus A Meah; Phil Schwab Read More
